Surrozen Inc

NASDAQ:SRZNUnited States

Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.

Contact Information

Headquarters

171 Oyster Point Blvd, Suite 400SOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-475-2820

Fax

302-655-5049

Executives

Non-Executive Chairman of the Board, Independent Director

David Woodhouse

President, Chief Executive Officer, Director

Craig Parker

Chief Financial Officer, Chief Operating Officer, Company Secretary

Charles Williams

Executive Vice President - Research

Yang Li

Independent Director

Anna Berkenblit